WinstonWınston
Back
Stock

Eurofins Scientific SE

ERFSF
51
Medical - Diagnostics & Research · Healthcare
Price
$85.60
+1.27 (+1.50%)
Market Cap
$14.79B
Exchange
Other OTC
Winston Score
51
Winston is curious
Mixed quality — meaningful strengths and weaknesses.
Data as of Sep 17, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality
Mixed
Growth
Good
Cash Flow
Strong
Stability
Mixed
Valuation
Strong
Dividends
Weak
Track this stock — start free trial

Share count falling — buybacks

−6.8% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 200.6M (2021) → 187.0M (2025)

§Winston Score History

The full picture

Eurofins Scientific is one of the world's largest laboratory testing companies. It analyzes food, water, pharmaceuticals, and environmental samples to make sure they are safe and meet regulations. Its customers include food producers, pharmaceutical companies, governments, and environmental agencies.

Eurofins makes money by charging fees for each test or through ongoing service contracts with its clients. The company operates over 900 laboratories across more than 60 countries, with major operations in Europe and North America. Its massive network of labs and wide range of accredited tests make it hard for smaller competitors to match its scale. Growth depends on expanding into new testing areas like genomics and clinical diagnostics, but the company carries significant debt from its acquisition-heavy strategy, which remains a key risk to watch.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+2.3% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+47.4% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

€0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

40.1%ownership

Insiders own a meaningful stake in the company

Cash Position

Cash flow positive

€716M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Eurofins Scientific SE is growing revenue at 2% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
13.5%
Thin — 13.5% gross margin
Profit after running costs
Operating Margin
13.5%
Healthy — 13.5% operating margin
Return on the money invested
ROCE
5.9%
Weak — 5.9% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+3.3%
Slow sales growth (+3.3% YoY)
Profit growth
EPS YoY
+45.5%
Earnings growing fast (+45.5% YoY)

Earnings growing 25%+ a year. The compounder zone.

How steady the profit is
EPS Consistency
5/8 quarters
Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
257%
Turns 257% of profit into real cash
Spare cash per sale
FCF Margin
8.6%
Modest free cash flow (8.6%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
1.51
Elevated debt (1.51)
Covers its interest
Interest Cover
2.95x
Tight — interest eats into profit (2.9x)

Interest coverage between 1 and 3. Profits cover interest, but with little room to spare.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
29.1x
Growth-priced — P/E 29.1

P/E above the market average. People are paying up for expected growth.

Cheaper or dearer next year
P/E vs Forward
+11.6
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (29.1 → 17.5)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend
Dividend Yield
0.94%
Small dividend — 0.94% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend record
Dividend Growth
-59.8%
Dividend cut (-59.8% YoY) — warning sign

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial